(+/-)-cis-3-Methylamino-cyclohexanol | 6982-37-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (+/-)-cis-3-Methylamino-cyclohexanol
• 英文别名: cis-3-Methylamino-cyclohexanol；(1S,3R)-3-(methylamino)cyclohexan-1-ol
• CAS: 6982-37-2；15942-10-6；89854-96-6
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: HQAAWQKUJZFQLK-RQJHMYQMSA-N

物化性质

• 熔点：
  87-88 °C
• 沸点：
  211.7±33.0 °C(Predicted)
• 密度：
  0.97±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-amino-3-bromo-5-methylphenyl)methanol 、 (+/-)-cis-3-Methylamino-cyclohexanol 生成 (1S,3R)-3-[(2-Amino-3-bromo-5-methyl-benzyl)-methyl-amino]-cyclohexanol
  参考文献：
  名称：

  CH609327

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 (+/-)-cis-3-Methylamino-cyclohexanol
  参考文献：
  名称：

  Burford et al., Journal of the Chemical Society, 1957, p. 2937,2940

  摘要：

  DOI：

文献信息

• Aminobenzyl-amides and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US03950393A1

  公开（公告）日：1976-04-13

  Compounds of the formula ##SPC1## Wherein R.sub.1 is hydrogen or aliphatic or aromatic carboxylic acyl, R.sub.2 is hydrogen, chlorine or bromine, R.sub.3 is fluorine, alkyl of 1 to 4 carbon atoms, trifluoromethyl, cyano, carbamoyl, carboxyl, carbalkoxy, alkoxy, acetyl, 1-hydroxyethyl or ##EQU1## where R.sub.6 and R.sub.7 are each alkyl, cycloalkyl, hydroxy-cycloalkyl or, together with each other and the nitrogen atom to which they are attached, pyrrolidino, piperidino or morpholino, and R.sub.4 and R.sub.5 are each hydrogen, alkyl of 1 to 5 carbon atoms, mono- or di-hydroxy (alkyl of 1 to 5 carbon atoms), alkenyl of 2 to 4 carbon atoms, cycloalkyl of 5 to 7 carbon atoms, mono- or di-hydroxy(cycloalkyl of 5 to 7 carbon atoms), benzyl, morpholinocarbonylmethyl or, together with each other and the nitrogen atom to which they are attached, pyrrolidino, piperidino, hexamethyleneimino, morpholino, N-methyl-piperazino or camphidino, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as anti-ulcergenics, secretolytics, antitussive, and stimulants of the production of the surfactant or antiatelectasis factor of the alveoli.

  公式为##SPC1##的化合物，其中R.sub.1是氢或脂肪或芳香族羧酰基，R.sub.2是氢、氯或溴，R.sub.3是1至4个碳原子的氟、烷基、三氟甲基、氰基、氨基甲酰基、羧基、氨基羧酸酯、烷氧基、乙酰基、1-羟基乙基或##EQU1##其中R.sub.6和R.sub.7分别是烷基、环烷基、羟基环烷基或与彼此及它们附着的氮原子一起的吡咯烷基、哌啶基或吗啉基，R.sub.4和R.sub.5分别是氢、1至5个碳原子的烷基、1至5个碳原子的单或双羟基烷基、2至4个碳原子的烯基、5至7个碳原子的环烷基、5至7个碳原子的单或双羟基环烷基、苄基、吗啉甲酰甲基或与彼此及它们附着的氮原子一起的吡咯烷基、哌啶基、己亚甲基亚胺基、吗啉、N-甲基哌嗪或香叶基亚胺基，以及其无毒、药理学上可接受的酸盐；这些化合物及其盐可用作抗溃疡、分泌溶解剂、止咳剂以及刺激肺泡表面活性物质或抗肺不张因子的产生的刺激剂。
• Aminobenzyl-amines and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US04101671A1

  公开（公告）日：1978-07-18

  Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or aliphatic or aromatic carboxylic acyl, R.sub.2 is hydrogen, chlorine or bromine, R.sub.3 is fluorine, alkyl of 1 to 4 carbon atoms, trifluoromethyl, cyano, carbamoyl, carboxyl, carbalkoxy, alkoxy, acetyl, 1-hydroxyethyl or ##STR2## where R.sub.6 and R.sub.7 are each alkyl, cycloalkyl, hydroxy-cycloalkyl or, together with each other and the nitrogen atom to which they are attached, pyrrolidino, piperidino or morpholino, and R.sub.4 and R.sub.5 are each hydrogen, alkyl of 1 to 5 carbon atoms, mono- or di-hydroxy (alkyl of 1 to 5 carbon atoms), alkenyl of 2 to 4 carbon atoms, cycloalkyl of 5 to 7 carbon atoms, mono- or di-hydroxy (cycloalkyl of 5 to 7 carbon atoms), benzyl, morpholinocarbonylmethyl or, together with each other and the nitrogen atom to which they are attached, pyrrolidino, piperidino, hexamethyleneimino, morpholino, N-methyl-piperazino or camphidino, Provided, however, that when R.sub.3 is carboxyl or carbalkoxy, R.sub.4 and R.sub.5 are other than hydrogen, alkyl, mono- or di-hydroxyalkyl, alkenyl, cycloalkyl, mono- or di-hydroxy-cycloalkyl or benzyl; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as anti-ulcerogenics.

  式为##STR1##的化合物，其中R.sub.1是氢或脂肪或芳香族羧酰基，R.sub.2是氢、氯或溴，R.sub.3是氟、1至4个碳原子的烷基、三氟甲基、氰基、氨基甲酰基、羧基、羧酯基、烷氧基、乙酰基、1-羟乙基或##STR2##其中R.sub.6和R.sub.7分别是烷基、环烷基、羟基环烷基或与彼此及它们附着的氮原子一起的吡咯啉基、哌啶基或吗啉基，R.sub.4和R.sub.5分别是氢、1至5个碳原子的烷基、1至5个碳原子的单或双羟基烷基、2至4个碳原子的烯基、5至7个碳原子的环烷基、5至7个碳原子的单或双羟基环烷基、苄基、吗啉甲酰甲基或与彼此及它们附着的氮原子一起的吡咯啉基、哌啶基、己亚甲基氨基、吗啉基、N-甲基哌嗪基或香叶基，但是，当R.sub.3是羧基或羧酯基时，R.sub.4和R.sub.5不是氢、烷基、单或双羟基烷基、烯基、环烷基、单或双羟基环烷基或苄基；以及其无毒、药理学可接受的酸盐。这些化合物及其盐可用作抗溃疡剂。
• [EN] IMIDAZO-PYRIDINE DERIVATIVES AS ACTIVIN-LIKE RECEPTOR KINASE (ALK4 OR ALK5) INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO-PYRIDINE SERVANT D'INHIBITEURS DE KINASE DU RÉCEPTEUR DE TYPE ACTIVINE
  申请人：NOVARTIS AG

  公开号：WO2009133070A1

  公开（公告）日：2009-11-05

  Compounds of formula (I): in free or salt or solvate form, where X, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  具有式（I）的化合物：以自由或盐或溶剂形式存在，其中X、R1、R2、R3和R4的含义如规范中所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的药物组合物和制备这些化合物的方法。
• Imidazo-Pyridine Derivatives as Activin-Like Receptor Kinase (ALK4 or ALK5) Inhibitors
  申请人：Leblanc Catherine

  公开号：US20110060004A1

  公开（公告）日：2011-03-10

  Compounds of formula (I): in free or salt or solvate form, where X, R 1 , R 2 , R 3 and R 4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式（I）的化合物：以自由形式、盐或溶剂形式存在，其中X、R1、R2、R3和R4的含义如规范中所示，对于治疗由ALK-5和/或ALK-4受体介导的疾病有用。还描述了包含这些化合物的制药组合物和制备这些化合物的过程。
• Organic Compounds
  申请人：Shaw Duncan

  公开号：US20100210641A1

  公开（公告）日：2010-08-19

  Compounds of formula I: in free or salt or solvate form, where R 1 , R 2 , R 3 and R 20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.

  式I的化合物：以自由或盐或溶剂形式存在，其中R1，R2，R3和R20具有规范中指定的含义，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的方法。这些化合物对于治疗炎症或阻塞性呼吸道疾病，如肺动脉高压，肺纤维化，肝纤维化，癌症，肌肉疾病，如肌肉萎缩和肌肉营养不良，以及全身性骨骼疾病，如骨质疏松症非常有用。